Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 6/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | EIF2AK3 | Q9NZJ5 | 2/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29331633 | 0.84 | DHFR (0.42) | EIF2AK3DHFR | |
| SCHEMBL19684526 | 0.81 | — | — | |
| SCHEMBL23042852 | 0.79 | ADORA2A (0.37) | DYRK1AADORA1ADORA2AEIF2AK3TLR7 | |
| SCHEMBL784185 | 0.78 | DYRK1A (0.39) | DYRK1AADORA1ADORA2ADHFRTLR7 | |
| SCHEMBL19678821 | 0.78 | SRC (0.37) | DYRK1AADORA1ADORA2ATLR7 | |
| SCHEMBL23057767 | 0.77 | DYRK1A (0.39) | DYRK1AEIF2AK3METAXL | |
| SCHEMBL30060936 | 0.77 | DYRK1A (0.39) | DYRK1AEIF2AK3METAXL | |
| SCHEMBL23057761 | 0.76 | EIF2AK3 (0.45) | DYRK1AEIF2AK3METAXL | |
| SCHEMBL30062927 | 0.76 | EIF2AK3 (0.45) | DYRK1AEIF2AK3METAXL | |
| SCHEMBL30060920 | 0.76 | DYRK1A (0.40) | DYRK1AADORA1ADORA2AEIF2AK3MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2017213825-A1 | TREATMENT METHODS HAVING REDUCED DRUG-RELATED TOXICITY AND METHODS OF IDENTIFYING THE LIKELIHOOD OF PATIENT HARM FROM PRESCRIBED MEDICATIONS | TABULA RASA HEALTHCARE, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | DYRK1A 4650/4885ADORA1 2833/4885ADORA2A 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.